logo
Stocks near record highs as oil prices fall after Israel-Iran ceasefire

Stocks near record highs as oil prices fall after Israel-Iran ceasefire

Fast Company11 hours ago

Oil prices are dropping further, and U.S. stocks are pulling close to their all-time high Tuesday on hopes that Israel's war with Iran will not damage the global flow of crude, even if a tentative truce seemed to fray under fire in the morning.
The S&P 500 was 1.2% higher in afternoon trading, following up on even bigger gains for stocks across Europe and Asia, after President Donald Trump said late Monday that Israel and Iran had agreed to a 'complete and total ceasefire.' The main measure of Wall Street's health is back within 1% of its record set in February after falling roughly 20% below during the spring.
The Dow Jones Industrial Average was up 518 points, or 1.2%, as of 1:56 p.m. Eastern time, and the Nasdaq composite was 1.5% higher.
The strongest action was again in the oil market, where a barrel of benchmark U.S. crude fell 5.4% to $64.82. Brent crude, the international standard, dropped 5.5% to $66.62.
The fear throughout the Israel-Iran conflict has been that it could squeeze the world's supply of oil, which would pump up prices for gasoline and hurt the global economy. Iran is a major producer of crude, and it could also try to block the Strait of Hormuz off its coast, through which 20% of the world's daily oil needs passes on ships.
Oil prices began falling sharply on Monday after Iran launched what appeared to be a limited retaliatory strike that did not target the production or movement of oil. They kept falling even after attacks continued past a deadline to stop hostilities early Tuesday. Trump later said that the ceasefire was 'in effect.'
Oil prices have dropped so much in the last two days that they're below where they were before the fighting began nearly two weeks ago.
With the global oil market well supplied and the OPEC+ alliance of producing countries steadily increasing production, oil prices could be headed even lower as long as the ceasefire holds and a lasting peace solution can be found, said Carsten Fritsch, commodities analyst at Commerzbank.
Falling oil prices should take some pressure off inflation, and that in turn could give the Federal Reserve more leeway to cut interest rates.
Wall Street loves lower rates because they can give the economy a boost by making it cheaper for U.S. households and businesses to borrow money to buy a car or build a factory. But they could also give inflation more fuel. That latter threat is why the Fed has been hesitant to cut rates this year after lowering them through the end of last year.
The Fed has said repeatedly that it wants to wait and see how much Trump's tariffs will hurt the economy and raise inflation before committing to its next move. So far, the economy seems to be holding up OK, though a report on confidence among U.S. consumers came in weaker on Tuesday than economists expected, while inflation has remained only a bit above the Fed's 2% target.
Trump, though, has been pushing for more cuts to rates. And two of his appointees to the Fed have said in the last week that they may consider cutting rates as soon as the Fed's next meeting next month.
Fed Chair Jerome Powell remains more cautious. He said again in testimony delivered to Congress Tuesday that the Fed is 'well positioned to wait to learn more about the likely course of the economy before considering any adjustments to our policy stance.'
Asked whether a cut could arrive as soon as July, Powell said, 'We will get to a place where we cut rates, sooner rather than later – but I wouldn't want to point to a particular meeting. I don't think we need to be in any rush because the economy is still strong.'
Such mixed messages had Treasury yields swiveling up and down in the bond market. The yield on the 10-year Treasury eased to 4.30% from 4.34% late Monday.
The two-year Treasury yield, which more closely tracks expectations for Fed action, fell to 3.82% from 3.84%.
On Wall Street, cruise operator Carnival steamed 6.7% higher after delivering a much stronger profit for the latest quarter than analysts expected. CEO Josh Weinstein said it's seeing strong demand from people booking cruises close to the departure date, and customers are spending strongly once on board. Carnival also raised its forecast for an underlying measure of profit for the full year.
Uber Technologies rose 7.8% after it said customers in Atlanta can use its app to ride in Waymo autonomous vehicles.
Coinbase Global rallied 11.4% as the cryptocurrency exchange rose with the price of bitcoin, which jumped back above $105,000.
In stock markets abroad, indexes rallied more than 1% everywhere from France to Germany to Japan following the announcement of the Israel-Iran ceasefire. Hong Kong's jump of 2.1% and South Korea's leap of 3% were two of the strongest moves.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Yahoo

time18 minutes ago

  • Yahoo

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation. This designation reflects Sanofi's commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Global Therapeutic Area Development Head, Immunology and Inflammation, Sanofi"Orphan drug designation for riliprubart marks an important milestone in our mission to address critical challenges in transplant medicine leveraging our expertise in immunology. Antibody mediated rejection represents a serious threat to transplanted organs and patient survival. Through riliprubart's innovative mechanism of action, we hope to bring forward a treatment option that could significantly improve outcomes for kidney transplant recipients." Riliprubart is currently being explored in multiple clinical studies across different indications in transplant and neurology. A phase 2 clinical study is currently ongoing, exploring its potential in kidney transplant recipients (NCT05156710). The study includes two patient cohorts: those at risk of developing rejection and those with active forms of antibody-mediated rejection. In addition, Sanofi is conducting two phase 3 studies exploring riliprubart in chronic inflammatory demyelinating polyneuropathy (CIPD), a rare neurological disorder, specifically in patients refractory to standard of care (MOBILIZE, clinical study identifier: NCT06290128), and in IVIg-treated patients (VITALIZE, clinical study identifier: NCT06290141). The broad clinical development program for riliprubart emphasizes Sanofi's commitment to exploring riliprubart's potential across multiple immune-mediated conditions with high unmet medical needs. About Riliprubart SAR445088 (riliprubart) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. Riliprubart is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. For more information on riliprubart clinical studies, please visit About AMRAntibody-mediated rejection is a serious complication that may arise after solid organ transplantation, occurring when the recipient's immune system produces antibodies that attack the transplanted organ. Sensitized recipients, who have pre-existing antibodies that target foreign antigens including those found on transplanted organs, face a high risk of developing antibody-mediated rejection. Subsequent immune response can lead to inflammation, organ damage, and organ failure if left untreated. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release

TPXimpact Holdings Full Year 2025 Earnings: UK£0.10 loss per share (vs UK£0.24 loss in FY 2024)
TPXimpact Holdings Full Year 2025 Earnings: UK£0.10 loss per share (vs UK£0.24 loss in FY 2024)

Yahoo

time19 minutes ago

  • Yahoo

TPXimpact Holdings Full Year 2025 Earnings: UK£0.10 loss per share (vs UK£0.24 loss in FY 2024)

Revenue: UK£77.3m (down 8.2% from FY 2024). Net loss: UK£9.16m (loss narrowed by 59% from FY 2024). UK£0.10 loss per share (improved from UK£0.24 loss in FY 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period TPXimpact Holdings shares are up 2.6% from a week ago. Before we wrap up, we've discovered 3 warning signs for TPXimpact Holdings (1 doesn't sit too well with us!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Teen nicknamed ‘Big Balls' leaves Trump's cost-cutting team after exposing wasteful spending
Teen nicknamed ‘Big Balls' leaves Trump's cost-cutting team after exposing wasteful spending

New York Post

time19 minutes ago

  • New York Post

Teen nicknamed ‘Big Balls' leaves Trump's cost-cutting team after exposing wasteful spending

A White House official confirmed to Fox News that a teenaged employee with the nickname 'Big Balls' has resigned from his post at the Department of Government Efficiency (DOGE), adding to the recent shakeup within the department. The now-former DOGE employee – whose real name is Edward Coristine – told Fox News Anchor Jesse Watters last month that his nickname originally came from his LinkedIn social media account. 'I use it as my LinkedIn username,' Coristine told Watters, prompting laughter from the host as well as DOGE leader Elon Musk and the rest of his team at the interview. 'Well, people on LinkedIn take themselves super seriously, and they're pretty averse to risk, and I was like, 'Well, I want to be neither of those things.' So, I just, I set it and honestly, I didn't think anybody would notice,' the DOGE employee continued, mocking the career-focused social media platform. A 19-year-old college student and software developer, Coristine was criticized by Democrats and liberal media pundits during DOGE's first few weeks of investigating wasteful and fraudulent spending in the federal government. 3 Teen Edward Coristine, who goes by the nickname Big Balls, resigned from his position at DOGE. Fox News Many were upset about the young, irreverently named government employee being given access to government records to pursue DOGE's work. During his interview with Watters, Coristine said he had been looking through US Treasury Department payment computers and finding a multitude of outgoing payments from the federal government that lacked details about who they were going to and why. 'So, one of our initiatives is to root out fraud and waste, and to do that we started looking at the payment computers. And, as mentioned earlier, there's no accounting of what payments actually go to in the payment computer,' Coristine said. 'You look at a specific line item — $20 million. You're like, 'OK, what is this money going to?' And for the majority of payment systems, it's like, 'Well, we don't really know.'' 3 Elon Musk shakes hands with President Donald Trump at the 2025 NCAA wrestling championship in Philadelphia, Penn. on March 22, 2025. AP He continued, saying the system that distributes taxpayer money 'literally has no checks and no accountability' to the American taxpayer, adding that it is a 'huge vector for fraud, waste, and abuse.' Coristine's resignation comes less than a month after Musk departed from the agency. Musk's departure was followed by the departure of several other staffers and special government employees at DOGE, which now includes Coristine. Musk has been heading DOGE since President Donald Trump took office in January. 3 President Donald Trump speaks to reporters in the Oval Office of the White House on May 30, 2025. Getty Images The department was tasked with cutting $2 trillion from the federal government's budget through efforts to slash spending, government programs and federal workforce. While DOGE was tasked with cutting $2 trillion from the budget, its efforts have led to roughly $180 billion in savings due to asset sales, contract cancellations, fraud payment cuts and other ways to eliminate costs, according to an update on DOGE's website. The savings translate to about $1,118 in savings per taxpayer, the website notes. Fox News Digital's Gabriel Hays contributed to this report.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store